Kumar A, Samavedi S, Bates A S, Giedelman Cuevas Camilo A, Coelho R F, Rocco B, Palmer K, Patel V R
Department of Urology, University of Central Florida College of Medicine and Global Robotics Institute, Florida Hospital-Celebration Health, FL, USA.
Department of Urology, University of Central Florida College of Medicine and Global Robotics Institute, Florida Hospital-Celebration Health, FL, USA.
Eur J Surg Oncol. 2015 Jul;41(7):837-43. doi: 10.1016/j.ejso.2015.04.006. Epub 2015 Apr 25.
Our goal was to evaluate the perioperative, functional and intermediate term oncological outcomes of robot assisted radical prostatectomy (RARP) in patients ≥ 70 years.
The study population (N = 3241) consisted of consecutive patients who underwent RARP for localized prostate cancer by a single surgeon (VP) from January 2008 through February 2012. A query of our Institutional Review Board approved registry identified 400 men ≥ 70 years of age, with good functional status (Charlson co-morbidity index < 3). These patients were propensity score matched to younger patients. Perioperative and postoperative functional and oncologic outcomes for the two groups were compared.
Full nerve sparing as well as the ease of nerve sparing were similar in 2 groups. Intra-operative complications were comparable. Postoperative complication occurrence rates were similar. At mean follow up of 34.1 months and 37.2 months respectively in younger and older patients, the continence rate was comparable in 2 groups (91.3% and 87.3%).Average time to continence and potency were similar in 2 groups. A greater proportion of younger patients became potent than elderly (52.3% vs 33.5%,p < 0.001).The biochemical recurrence (BCR) rate was comparable in 2 groups (7.8% vs 8.3%; p = 0.79). The mean time to BCR was also comparable in 2 groups (16 months vs 22.6 months; p = 0.07).
In appropriately selected patients (minimal comorbidities with CCI ≤ 2, life expectancy >10 years, localized prostate cancer) RARP is a reasonable option in patients ≥ 7 0 years and provides comparable perioperative, functional and intermediate term oncologic outcomes as compared to younger patients.
我们的目标是评估70岁及以上患者行机器人辅助根治性前列腺切除术(RARP)的围手术期、功能及中期肿瘤学结局。
研究人群(N = 3241)包括2008年1月至2012年2月期间由同一位外科医生(VP)为局限性前列腺癌行RARP的连续患者。查询经机构审查委员会批准的登记册,确定了400名70岁及以上、功能状态良好(Charlson合并症指数<3)的男性。这些患者与年轻患者进行倾向评分匹配。比较两组的围手术期、术后功能及肿瘤学结局。
两组的完全保留神经以及保留神经的难易程度相似。术中并发症相当。术后并发症发生率相似。年轻患者和老年患者的平均随访时间分别为34.1个月和37.2个月,两组的控尿率相当(91.3%和87.3%)。两组的平均控尿时间和恢复勃起功能时间相似。年轻患者恢复勃起功能的比例高于老年患者(52.3%对33.5%,p<0.001)。两组的生化复发(BCR)率相当(7.8%对8.3%;p = 0.79)。两组的平均BCR时间也相当(16个月对22.6个月;p = 0.07)。
在适当选择的患者(合并症少,CCI≤2,预期寿命>10年,局限性前列腺癌)中,RARP对于70岁及以上患者是一个合理的选择,与年轻患者相比,其围手术期、功能及中期肿瘤学结局相当。